Lanreotid Sun (Lanreotide)

Lanreotide mimics natural somatostatin and binds to somatostatin receptors (mainly SSTR2 and SSTR5) on endocrine cells. This binding blocks adenylate cyclase, reduces cyclic AMP, and inhibits the release of growth hormone, insulin, glucagon, and other peptide hormones, thereby controlling disease activity.

The dose and dosing interval of Lanreotid Sun are determined by the prescribing clinician based on the patient’s condition, disease severity, and response to therapy. The prescriber will select the appropriate regimen and adjust it as needed.

The safety of lanreotide in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To request Lanreotid Sun, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Lanreotid Sun (lanreotide) and other analogues such as octreotide share the same mechanism of receptor binding but differ in dosing frequency and formulation. Lanreotide is often administered as a long‑acting injectable every 4‑8 weeks, offering less frequent injections compared with some short‑acting alternatives.

Lanreotid Sun should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging to maintain stability until it is administered.

Lanreotid Sun is given as a subcutaneous injection by a qualified healthcare professional. The injection site is typically the abdomen or thigh, and the administration schedule is set by the treating physician based on the patient’s therapeutic needs.

Serious risks include pancreatitis, severe hypersensitivity reactions (including anaphylaxis), acute cholecystitis, and significant hyperglycaemia that may require medical management. Patients should be monitored regularly for these conditions, especially if they have pre‑existing risk factors.

Lanreotid Sun is contraindicated in patients with known hypersensitivity to lanreotide or any excipients in the formulation. Caution is advised for individuals with severe hepatic impairment, uncontrolled diabetes, or active gallbladder disease, and it should be avoided in pregnant women unless clearly indicated.